Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on August 14, 2017, reporting events that occurred on August 8, 2017. The filing details the conversion of unregistered debt securities into common stock following the closing of a registered public offering.
Key Financial Metrics and Transaction Details
- Debt Converted: $4,710,000 in principal from Bridge Notes.
- Accrued Interest Converted: $76,240.
- Total Conversion Value: $4,786,240.
- Shares Issued: 1,547,067 shares of common stock.
- Conversion Price: $3.09 per share.
- Public Offering Price: $4.125 per share (Conversion price was 75% of this amount).
Material Changes
The primary material change is the reduction of the company's debt load by $4,710,000 and the corresponding increase in outstanding common stock by 1,547,067 shares. This transaction was executed by Leonard Mazur, the Company's Executive Chairman, Secretary, and Director, who held the convertible promissory notes.
Guidance, Outlook, and Risks
The filing does not provide new financial guidance, outlook, or management commentary regarding future operations. The transaction was a contractual conversion based on the terms of the Bridge Notes, which allowed conversion at the sole discretion of the lender at 75% of the public offering price. No specific risks or contingencies were disclosed in this report beyond the standard incorporation by reference of the note terms.
Investor Verification Checklist
- Verify the total number of outstanding shares post-conversion to assess dilution impact.
- Review the "Form of Bridge Note" (Exhibit 10.1 to the March 31, 2017 Form 10-Q) for complete terms and conditions.
- Confirm the relationship and potential conflicts of interest regarding the lender, Leonard Mazur, who is also an executive and director.
- Check subsequent filings for the impact of this equity issuance on the company's capital structure and cash flow.